Singapore markets open in 2 hours 51 minutes

CStone Pharmaceuticals (2616.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
1.420+0.090 (+6.77%)
At close: 04:08PM HKT
Full screen
Previous close1.330
Open1.350
Bid1.420 x 0
Ask1.440 x 0
Day's range1.320 - 1.480
52-week range0.800 - 3.270
Volume3,003,500
Avg. volume2,832,221
Market cap1.811B
Beta (5Y monthly)0.17
PE ratio (TTM)N/A
EPS (TTM)-0.310
Earnings date13 Aug 2024 - 19 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.53
  • PR Newswire

    CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.

  • PR Newswire

    CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl

  • PR Newswire

    CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Servier, a global independent pharmaceutical group, today announced an agreement whereby Servier acquires from CStone the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore.